Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has a cash flow conversion efficiency ratio of 0.625x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.73 Million) by net assets ($-45.97 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AMRX cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Amneal Pharmaceuticals, Inc. Class A Common Stock - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Amneal Pharmaceuticals, Inc. Class A Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Amneal Pharmaceuticals, Inc. Class A Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Amneal Pharmaceuticals, Inc. Class A Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Balchem Corporation
NASDAQ:BCPC
|
0.031x |
|
Sai Gon Thuong Tin Commercial Joint Stock Bank
VN:STB
|
-0.952x |
|
EVN AG
VI:EVN
|
-0.007x |
|
All Winner Technology Co Ltd
SHE:300458
|
0.041x |
|
TECO Electric & Machinery Co Ltd
TW:1504
|
-0.013x |
|
Hangzhou Great Star Industrial Co Ltd
SHE:002444
|
0.030x |
|
Focuslight Technologies Inc. A
SHG:688167
|
N/A |
|
TEMENOS AG UNSP.ADR/1
F:TE8A
|
0.194x |
Annual Cash Flow Conversion Efficiency for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2025)
The table below shows the annual cash flow conversion efficiency of Amneal Pharmaceuticals, Inc. Class A Common Stock from 2015 to 2025. For the full company profile with market capitalisation and key ratios, see Amneal Pharmaceuticals, Inc. Class A Com (AMRX) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.96 Million | $339.99 Million | 57.017x | +960.53% |
| 2024-12-31 | $-44.54 Million | $295.10 Million | -6.626x | -217.54% |
| 2023-12-31 | $61.30 Million | $345.58 Million | 5.637x | +1709.14% |
| 2022-12-31 | $208.93 Million | $65.10 Million | 0.312x | -52.71% |
| 2021-12-31 | $366.97 Million | $241.82 Million | 0.659x | -37.98% |
| 2020-12-31 | $356.74 Million | $379.00 Million | 1.062x | +21508.92% |
| 2019-12-31 | $346.79 Million | $1.71 Million | 0.005x | -98.24% |
| 2018-12-31 | $896.36 Million | $250.23 Million | 0.279x | +144.77% |
| 2017-12-31 | $-375.58 Million | $234.19 Million | -0.624x | +4.65% |
| 2016-12-31 | $-175.94 Million | $115.06 Million | -0.654x | -16.52% |
| 2015-12-31 | $-186.87 Million | $104.88 Million | -0.561x | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more